Clinical Trial Update: Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating a triple combination of pomalidomide, marizomib, and low-dose dexamethasone in relapsed and refractory multiple myeloma; the trial has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Marizomib (marizomib)
• Pomalyst (pomalidomide)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma in Relapse, Refractory Multiple Myeloma | Phase 1 | Status: COMPLETED